以下文章来源于阿基米德Biotech ，作者阿基米德君 阿基米德Biotech . 生物医药第三方独立观察，客观中立，深入浅出，松弛愉悦，写作纯为兴趣，不接广告 超长续航模式。 来源 | 阿基米德Biotech （ID：ArchimedesBiotech） 资本寒冬，一家上市Bi o t e c h也没有挂掉。 1 8A生物科技七年之痒，7 0家公司（含摘B）仍然整整齐齐，一家没少，即使市值最小 的北海康成账上现金仅剩1亿元，但管理层认为2025年有足够的营运资金，即使诺辉健 康复牌暂时没有进展，但离生死大限还有5个月。 中国创新药处于少年时代，（在上市公司层面）有着足够的容错率和包容度，如同《百 年孤独》中初创的"马孔多"，这里全是年轻人，没有死亡，自然没有墓地。 然而，站在中国创新药1 0年节点之上，两大蜕变还是发生了。 今 非 昔 比 ， 《 创 新 药 供 给 侧 改 革 》 （ 2021 年 7 月 ） 指 出 的 内 卷 和 泡 沫 ， 如 今 都 不 再 严 重。 一是行业主要矛盾的蜕变，从同质化竞争的内部矛盾，转为中国生物科技快速崛起与美 国维持生物科技创新领域领导地位之间的外部矛盾。 二是创 ...

恒生指数收涨0.78% 南向资金净买入额超210亿港元 金十数据4月22日讯，港股主要股指午后回暖；截至收盘，香港恒生指数收涨0.78%，恒生科技指数涨 0.24%。南向资金净买入213.6亿港元。恒生指数全日成交额达2513.82亿港元。盘面上，医药、黄金股 今日大涨，心泰医疗(02291.HK)涨超47%后停牌，歌礼制药(01672.HK)涨超24%，药明合联(02268.HK) 涨超9%；赤峰黄金(06693.HK)涨8.59%，山东黄金(01787.HK)涨超7%，招金矿业(01818.HK)、胜龙国际 (01182.HK)收涨超5%。受外卖大战消息影响，京东美团齐齐收跌，美团(03690.HK)收跌4.62%，京东 (09618.HK)收跌6.32%。 ...

香港 恒生指数收涨0.78%， 恒生科技指数涨0.24%。 药明合联涨超9%， 赤峰黄金涨超8%， 山东黄金 涨超7%， 小米集团涨超5%； 京东集团跌超6%， 美团跌超4%， 中国中免跌超3%。 ...

Core Viewpoint - The CSI Hong Kong-Shanghai-Macau Pharmaceutical R&D Service Index has shown a decline of 20.89% over the past month, while it has increased by 1.05% over the last three months and decreased by 2.89% year-to-date [1] Group 1: Index Performance - The CSI Hong Kong-Shanghai-Macau Pharmaceutical R&D Service Index is currently at 1344.91 points [1] - The index was established on December 29, 2017, with a base point of 1000.0 [1] Group 2: Index Composition - The top ten weighted companies in the index are: WuXi Biologics (18.47%), WuXi AppTec (13.28%), Hangzhou Tigermed Consulting (7.0%), and others [1] - The index consists of no more than 50 listed companies providing drug research, development, and production services [1] Group 3: Market Distribution - The market distribution of the index holdings is as follows: Shenzhen Stock Exchange (35.66%), Shanghai Stock Exchange (32.49%), and Hong Kong Stock Exchange (31.85%) [1] Group 4: Industry Breakdown - The industry composition of the index holdings includes: Pharmaceutical and Biotechnology Services (86.14%), Chemical Drugs (11.95%), Agricultural Chemicals (1.39%), and Biopharmaceuticals (0.52%) [2] Group 5: Index Adjustment Mechanism - The index samples are adjusted biannually, with adjustments occurring on the next trading day after the second Friday of June and December [2] - Special circumstances may lead to temporary adjustments of the index [2]

基金管理人在一季报中表示，本基金看好医药板块确定性增长的比较优势，重点配置了创新药及其研发服务外包产业链、医疗设备及耗材、AI医疗等相关 细分赛道。 截至4月18日，招商前沿医疗保健股票A近三个月复权单位净值增长率为8.43%，位于同类可比基金33/54；近半年复权单位净值增长率为-4.05%，位于同类可 比基金42/54；近一年复权单位净值增长率为4.11%，位于同类可比基金25/54；近三年复权单位净值增长率为-35.68%，位于同类可比基金41/46。 AI基金招商前沿医疗保健股票A（011373）披露2025年一季报，第一季度基金利润7093.67万元，加权平均基金份额本期利润0.0663元。报告期内，基金净值 增长率为14.69%，截至一季度末，基金规模为5.45亿元。 该基金属于标准股票型基金，长期投资于医药医疗股票。截至4月18日，单位净值为0.473元。基金经理是李佳存，目前管理4只基金。其中，截至4月18日， 招商创新增长混合A近一年复权单位净值增长率最高，达7.71%；招商医药健康产业股票最低，为-1.74%。 通过所选区间该基金净值增长率分位图，可以观察该基金与同类基金业绩比较情况。图为 ...

Investment Rating - The report assigns an "Outperform" rating to multiple companies in the Hong Kong healthcare sector, indicating an expected total return over the next 12-18 months that exceeds the relevant market benchmark [1][19][25]. Core Insights - The report highlights President Trump's executive order aimed at lowering prescription drug prices through various measures, including optimizing federal healthcare programs and enhancing regulatory transparency [4][6]. - Key aspects of the executive order include standardizing negotiation timelines for drug prices, promoting competition through accelerated approvals for generics and biosimilars, and increasing transparency in pharmacy benefit manager (PBM) fees [7][4]. Summary by Sections Investment Focus - Companies rated "Outperform" include JD Health, WuXi Biologics, Alibaba Health, and many others, reflecting a positive outlook for the healthcare sector in Hong Kong [1]. Policy Developments - The executive order includes provisions for negotiating drug prices after a uniform timeline of 13 years for both small-molecule and large-molecule drugs, which aims to balance innovation incentives [4][7]. - The order also emphasizes the need for Congressional cooperation for full implementation, suggesting a prolonged timeline for these changes [6]. Market Trends - The report notes the importance of monitoring the evolution of U.S. tariff policies and domestic demand as they relate to the pharmaceutical industry [3]. - It also discusses the recovery of domestic consumption demand policies, which could positively impact the healthcare sector [3].

Investment Rating - The industry investment rating is "Outperform the Market" [1][50]. Core Insights - Eli Lilly's first oral small molecule GLP-1 drug, Orforglipron, has successfully completed Phase 3 clinical trials, which is expected to change the landscape of weight loss medications [3][4]. - The ACHIEVE-1 trial showed that Orforglipron significantly reduced HbA1c levels by 1.3% to 1.6% from a baseline of 8.0% after 40 weeks, with over 65% of patients achieving HbA1c levels ≤6.5% [3][4]. - Patients receiving the highest dose of Orforglipron lost an average of 7.3 kg, indicating potential for further weight loss [4]. - Eli Lilly plans to submit a global application for Orforglipron for weight management by the end of this year and for type 2 diabetes treatment in 2026 [4][5]. Summary by Sections Industry Overview - The successful Phase 3 trial of Orforglipron positions it as a potential second oral GLP-1 drug in the U.S., following Novo Nordisk's Rybelsus [5]. Investment Strategy - Focus on "innovation," "overseas expansion," "equipment upgrades," and "consumer recovery" as key investment themes [7]. - Recommended companies include innovative drug developers and those with strong overseas market potential [7]. Key Companies to Watch - **Nocera Health**: Expected to achieve over 1 billion yuan in revenue from its core product, with a projected 49% year-on-year growth [8]. - **Sihuan Pharmaceutical**: Strong fundamentals with a stable growth outlook, particularly in the ADC market [11]. - **China Biopharmaceutical**: Rapid revenue growth with a focus on innovative products [13]. - **Aier Eye Hospital**: Benefiting from increasing demand in ophthalmology and ongoing overseas expansion [22]. Market Performance - The pharmaceutical sector saw a decline of 0.36% last week, while the broader market index rose by 0.59% [25][36].

Summary of the Earnings Call Transcript Company Overview - The company discussed is **XTC**, a global leader in the CRDMO (Contract Research, Development, and Manufacturing Organization) sector, specifically focused on the ADC (Antibody-Drug Conjugate) market, covering all four components of ADCs: antibodies, linkers, payloads, and drug substances [1][2]. Key Financial Highlights - **Revenue Growth**: The company reported a revenue increase of approximately **91%** year-over-year, reaching **4.052 billion RMB** [2][14]. - **Net Profit**: Net profit surged by **277%**, exceeding **1.07 billion RMB** [2][14]. - **Active Projects**: The company has **194 active ICMC projects** and signed **53 new ICMC projects** in the past year [2][3]. - **Employee Growth**: The workforce exceeded **2000 employees** by the end of the previous year [2][12]. Operational Highlights - **Production Capacity**: The company delivered over **300 GMP batches** across various components, showcasing strong operational execution [4]. - **Client Base**: The client count approached **500**, with **32%** of revenue coming from **13 out of the top 20 pharmaceutical companies** globally [4][5]. - **Geographical Revenue Distribution**: North America accounted for nearly **50%** of revenue, with significant growth in China and Europe [6]. Technological Advancements - The company is actively investing in technology upgrades, including advancements in linker and payload technologies, with new products like **DARX** and **X-Link** introduced [6][7]. - The company synthesized over **14,000 different molecules**, indicating a robust pipeline in both traditional ADCs and newer XTC projects [8]. Future Outlook - **2025 Focus Areas**: The company aims to execute multiple PPQ projects, expand production capacity with the new **DP3** facility, and submit BLA projects to regulatory bodies in China and the U.S. [13][20]. - **Capital Expenditure**: Projected capital expenditure for 2024 is around **1.5 billion RMB**, primarily for capacity expansion in Singapore and Wuxi [18]. Market Dynamics - The company noted a strong demand for ADCs, with a backlog of orders growing by **87%** year-over-year, particularly in North America [17]. - The management expressed confidence in maintaining a high growth rate, projecting that the annual growth rate will exceed the industry average over the next five years [20]. Risks and Challenges - Profit margins may experience fluctuations due to new production line ramp-ups and external economic conditions [16][34]. - The competitive landscape is intensifying with new entrants from Japan and South Korea, but the company believes its expertise and established client relationships will mitigate risks [25][27]. Additional Insights - The company has a strong cash position, with **4 billion RMB** in cash reserves, supporting future capital expenditures [19]. - The management emphasized the importance of maintaining operational efficiency and cost control to sustain profit margins [15][34]. This summary encapsulates the key points discussed during the earnings call, highlighting the company's performance, operational strategies, and future outlook in the ADC market.

Investment Rating - The industry investment rating is "Outperform the Market" [52] Core Views - The report emphasizes the ongoing disruptions caused by the US-China tariff policies and suggests focusing on opportunities in non-US markets and import substitution [4][9] - The report highlights that the adjustment of tariffs is expected to impact the trade of pharmaceutical products between China and the US, while companies primarily exporting to markets outside the US will be less affected [4][9] Summary by Sections Tariff Policy Overview - Since April 2, 2025, the US government has imposed a 34% "reciprocal tariff" on Chinese goods, with frequent adjustments to tariff rates and exemptions for certain pharmaceutical products [4][5] - As of April 11, 2025, the tariff rates for bilateral trade between China and the US have been adjusted to 125%, with China indicating it will not respond to further tariff increases from the US [5] Opportunities in the Biopharmaceutical Sector - The report identifies potential for domestic products to increase market share in the blood products sector due to tariff impacts, particularly for albumin, where US imports are significant [9] - It suggests monitoring companies such as Palin Bio, Tiantan Bio, and Huashan Bio for potential growth in market share as import costs rise [9] Medical Devices - The report notes that the tariff policies and anti-dumping investigations are likely to accelerate the domestic substitution process in medical devices, particularly in electrophysiology and imaging fields [10] - Companies like Yirui Technology and United Imaging are highlighted as making progress in domestic production capabilities [10] Investment Strategies - The report recommends focusing on "innovation," "overseas expansion," "equipment upgrades," and "consumption recovery" as key investment themes [12] - Specific companies to watch include BeiGene, Mindray, and Xiamen Innovax for their innovative products and overseas market potential [12] Key Companies to Watch - Notable companies include: - **Nocera Biopharma**: Expected to achieve significant revenue growth with its core product, demonstrating strong cash flow and reduced losses [13][14] - **Sino Biopharmaceutical**: Rapid revenue growth with a focus on innovative products and a strong pipeline [18] - **Kexing Biopharma**: Stable domestic business with promising overseas expansion [18] - **Wuxi Biologics**: Recognized for its strong technical capabilities and expanding overseas operations [22] Market Performance - The report notes a decline in the pharmaceutical sector, with a 5.61% drop in the past week, while the overall market saw a smaller decline [31][42] - The biopharmaceutical sector is highlighted as having the smallest decline among sub-sectors, indicating relative resilience [44]

Core Viewpoint - The Hong Kong pharmaceutical ETF has shown strong performance, driven by significant inflows from mainland investors and positive developments in the biotechnology sector [1][3]. Group 1: Market Performance - As of April 14, the Hong Kong pharmaceutical ETF (513700.SH) increased by 3.63%, with major constituents like Hansoh Pharmaceutical rising by 3.98% and WuXi AppTec increasing by 7.13% [1]. - Southbound funds have seen a net inflow exceeding HKD 82 billion this week, indicating a strong interest from mainland investors in Hong Kong stocks [3]. Group 2: Sector Dynamics - The innovative drug development sector is performing strongly, benefiting from a recovery in global biotechnology financing and advancements in clinical pipelines [3]. - The antibody-drug conjugate (ADC) field remains active, with improved commercialization capabilities driving valuation recovery [3]. - The overall biopharmaceutical production sector is experiencing a rally, supported by improved capacity utilization and enhanced market confidence due to policy support [3]. Group 3: Analyst Insights - According to Shenwan Hongyuan, the valuation of the Hang Seng Hong Kong Stock Connect Healthcare Index constituents is at historical lows, with about 70% of stocks having a PE percentile below 50% [3]. - Guojin Securities emphasizes the global competitiveness of Chinese innovative drugs, with clinical pipeline progress and international achievements boosting industry sentiment [3]. - Both institutions highlight structural opportunities in the Hong Kong healthcare sector due to technological innovation and valuation advantages, although they do not provide specific product recommendations [3]. Group 4: Broader Market Trends - The market is exhibiting sector rotation characteristics, with technology growth and cyclical sectors showing divergent performance [4]. - The semiconductor and AI sectors are gaining traction due to domestic substitution and policy support, while the renewable energy sector faces adjustments due to overcapacity concerns [4]. - Within the pharmaceutical sector, innovative drugs and devices are outperforming generic drugs, reflecting market pricing differences based on R&D capabilities [4].